Last updated: February 4, 2026
What are the case’s basic facts and procedural posture?
Array BioPharma Inc. filed a patent infringement lawsuit against Sandoz Inc. in the District of Colorado on March 22, 2022. The case number is 1:22-cv-01316. Array asserts that Sandoz's generic version of a cancer treatment infringes its patents. The patents in dispute cover specific methods and formulations of the drug.
Sandoz filed a paragraph IV certification under the Hatch-Waxman Act, challenging the patent's validity and asserting that its generic does not infringe. Array responded by filing a claim for patent infringement, triggering an automatic 30-month stay of FDA approval under Hatch-Waxman provisions.
What patents are involved?
Array's patent portfolio includes U.S. Patent Nos. 9,109,132 and 9,824,217, both claiming methods of inducing apoptosis in specific cancer cells and formulations thereof. The patents issued in 2015 and 2016, respectively, and claim compositions and methods used in cancer treatments.
What are the key legal issues?
The main issues involve patent validity, infringement, and the scope of the patents. Sandoz challenges whether its generic product infringe the patents and whether those patents are invalid under § 101 (subject matter eligibility), § 102 (novelty), § 103 (obviousness), and § 112 (written description and enablement).
What is the current procedural status?
As of the latest update, the case remains in early stages. Sandoz filed its Paragraph IV certification on September 2022. Array responded with an infringement complaint in March 2022. Discovery has not yet started, and no trial date has been scheduled.
What are the implications for patent enforcement?
The case exemplifies typical Hatch-Waxman litigation, where patent holders seek to enforce exclusivity rights while facing challenges from generic drug companies. It underscores the importance of robust patent drafting, particularly in method-of-treatment claims, and highlights the strategic use of Paragraph IV certifications to delay generic entry.
How is the legal landscape shaping around similar cases?
In recent years, courts have scrutinized method-of-treatment patents closely, especially concerning § 101 challenges. The outcome can depend heavily on claim language, with courts assessing whether claims cover patent-eligible subject matter. Validity defenses such as obviousness (§ 103) are common, especially for complex chemical inventions.
The Federal Circuit has also stressed the importance of claiming specific methods or formulations to avoid patent invalidity. Courts scrutinize asserted patents for written description and enablement, especially if the claims encompass broad methods without sufficient disclosure.
What are potential outcomes?
- Infringement Finding: If Sandoz's generic falls within the patent claims, and the patents are held valid, the court could issue an injunction or damages.
- Invalidity Ruling: Validity challenges, especially under §§ 101 or 103, could result in patent invalidation, clearing the way for Sandoz's product approval.
- Settlement or Litigation Dismissal: Parties could settle, possibly involving licensing agreements or settlement terms, or Sandoz could succeed in invalidity defenses, leading to the case's dismissal.
What lessons does this case offer for patent strategists?
- Clearly define method claims to enhance validity and enforceability.
- Consider potential challenges under § 101 and art-specific invalidity defenses.
- Use Paragraph IV strategically to delay generic entry, but prepare for lengthy litigation.
- Maintain comprehensive disclosures to support method claims and prevent invalidity.
Key Takeaways
- Array's patents relate to cancer treatment methods and formulations, vital in its IP portfolio.
- Sandoz challenges the patents through a Paragraph IV certification, initiating Hatch-Waxman litigation.
- Patent validity under § 101 and § 103 remains a critical battleground.
- Early procedural stages leave the case open to multiple potential outcomes, including invalidity or infringement rulings.
- The case highlights the importance of claim drafting in method patents and the strategic use of Paragraph IV notices.
5 FAQs
1. What is the significance of a Paragraph IV certification?
It indicates a generic manufacturer believes a patent is invalid or not infringed, triggering patent litigation and an automatic stay against FDA approval for 30 months.
2. How does patent invalidity under § 101 affect litigation?
If courts find patents claiming abstract ideas or ineligible subject matter, the patents can be invalidated, clearing the way for generic products.
3. What is the typical timeline for such Hatch-Waxman cases?
From Paragraph IV notice to resolution, cases often span 2-4 years, depending on complexity, motions, and settlement negotiations.
4. How do courts evaluate method-of-treatment patent claims?
Courts assess whether claims are sufficiently specific, novel, and properly supported by the patent disclosure, especially regarding patent-eligible subject matter.
5. What strategies can patent holders employ?
Draft detailed, specific claims, consider multiple claim types, and anticipate validity challenges, especially under § 101 and § 103.
References
[1] 35 U.S. Code § 271 (Infringement of patent rights).
[2] Hatch-Waxman Act, 21 U.S.C. §§ 355, 355(j).
[3] Federal Circuit decisions on patent eligibility and validity.
[4] Court filings and docket entries from case 1:22-cv-01316.
